CD8A and neoplasm: The PB@MC group showed a substantial increase in the presence of T cells within the tumour, particularly CD8+ T cells, which reached ~33% of total CD3+ cells in tumours treated with PB@MCs, which was significantly higher than that in other groups (p < 0.001) (Fig. 5E and Supplementary Fig. 16).